Charles Schwab
SABS icon

Charles Schwab’s SAB Biotherapeutics SABS Stock Holding History

Charles Schwab’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,624
Closed -$11.2K – 3510
2023
Q4 		$11.2K Hold
1,624
– – ﹤0.01% 3521
2023
Q3 		$10.2K Hold
1,624
– – ﹤0.01% 3563
2023
Q2 		$13.5K Hold
1,624
– – ﹤0.01% 3588
2023
Q1 		$7.14K Hold
1,624
– – ﹤0.01% 3544
2022
Q4 		$9.58K Hold
1,624
– – ﹤0.01% 3533
2022
Q3 		$12K Hold
1,624
– – ﹤0.01% 3504
2022
Q2 		$24K Buy
+1,624
New +$34.1K ﹤0.01% 3509
2022
Q1 		– Sell
-1,000
Closed -$79K – 3614
2021
Q4 		$79K Buy
+1,000
New +$93.8K ﹤0.01% 3467

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Charles Schwab's SABS Position: Q1 2024 in Review

Charles Schwab sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 1,624 shares — an estimated $11.2K sold.

Charles Schwab first reported a position in SABS in Q4 2021 and held it in 8 quarters. The position peaked at $79K in Q4 2021. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Charles Schwab reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 1,624 SAB Biotherapeutics shares in Q1 2024, an estimated $11.2K.
  • Charles Schwab first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 8 quarters.
  • Charles Schwab's SAB Biotherapeutics position peaked at $79K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.